Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
0.14Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: operational and financial discipline produced a notable EBITDA beat, margin expansion, improved installed base metrics, and strong liquidity, but top-line performance remains pressured with declining sales, softer device placements, and structural macro/competitive headwinds. Management is taking concrete commercial and product actions and maintained EBITDA guidance while trimming revenue expectations, positioning 2026 as an execution/stabilization year with recovery expected in 2027.Company Guidance
Adjusted EBITDA Outperformance
Adjusted EBITDA of $8.5M in Q1, up 17% year-over-year and representing a 13.1% margin; result was well above the prior guidance range of $3.5M to $5.5M.
Strong Adjusted Gross Margin
Adjusted gross margin expanded to 72.2% in Q1 versus 71.9% in prior year, demonstrating margin resilience despite lower revenue.
Improved Profitability and Cost Discipline
GAAP operating expenses decreased to $46.2M from $60.6M a year ago (driven by lower S&M, G&A and legal costs), contributing to an improved net loss of $6.6M versus $10.1M in prior year.
Growing Installed Base and Reduced Churn
Active installed base grew to 36,400 systems, up 4% year-over-year, while device churn declined 40% year-over-year, signaling improved provider retention and reactivation.
Strong Cash Position and Manageable Near-Term Debt
Ended the quarter with $204.4M in cash, cash equivalents and restricted cash; company stated confidence in addressing the October 2026 debt maturity of approximately $103M based on current cash flow expectations.
Maintained Full-Year Adjusted EBITDA Guidance
Despite lowering revenue guidance, management maintained adjusted EBITDA guidance of $35M to $45M, reflecting operational leverage and margin strength.
Active Innovation and Board Strengthening
Advancing innovation initiatives including booster portfolio overhaul, Keravive (HydraScalp) relaunch later this quarter, a clinically-backed booster expected in Q4, and development of a next-generation Hydrafacial device targeting a 2028 launch; added three independent directors with medtech/aesthetics experience.
DE:V7A0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:V7A0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €0.76 | €0.48 | -36.42% |
Mar 12, 2026 | €0.95 | €0.88 | -7.85% |
Nov 06, 2025 | €1.08 | €1.19 | +10.19% |
Aug 07, 2025 | €1.37 | €1.62 | +18.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Beauty Health (DE:V7A0) report earnings?
Beauty Health (DE:V7A0) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Beauty Health (DE:V7A0) earnings time?
Beauty Health (DE:V7A0) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Beauty Health stock?
The P/E ratio of Beauty Health is N/A.
What is DE:V7A0 EPS forecast?
DE:V7A0 EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.
